Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Neurohormonal modulation in chronic heart failure

R Ferrara1, F Mastrorilli1, G Pasanisi1, S Censi1, N D'aiello1, A Fucili1, M Valgimigli1,2 and R Ferrari*,1

a Cardiovascular Research Center, `S. Maugeri'Foundation, Gussago Brescia, Italy
b Chair of Cardiology, University of Ferrara, Arcispedale S. Anna, Ferrara, Italy

* Correspondence: Professor Roberto Ferrari, Cattedra di Cardiologia, Universita' di Ferrara, H. S. Anna, UniO Operativa di Cardiologia-UTIC, C.rso Giovecca 203, 44100 Ferrara, Italy.

Abstract

During the past 50 years there have been vast improvements in the treatment of chronic heart failure (CHF). CHF was initially considered to be a cardio-renal problem - an acute disorder leading to volume expansion and oedema. Diuretics and digitalis were the only available treatments. Subsequently, CHF was considered to be the result of both myocardial dysfunction and increased tone in the pulmonary and peripheral circulations. The presence of peripheral vasoconstriction suggested that circulatory failure was an important component of the disease, and vasodilators were added to therapy. In the more recent past, experimental and clinical studies have demonstrated that CHF is also characterized by increased neurohormonal activation. This has led to the use of angiotensin-converting enzyme inhibitors, beta-blockers and spironolactone in CHF. Increased neurohormonal activity is now recognized as one of the major pathophysiological factors that contribute to the progression of CHF. Activation of neurohormonal mechanisms is only compensatory in the short term; chronic activation produces detrimental changes in the myocardirun, kidneys and peripheral vasculature. This article provides an overview of the key neurohormonal systems that are activated in CHF.

Key Words: Chronic heart failure • left ventricular dysfunction • neurohormones • ventricular remodelling

References

  1. Cleland JGF, for the Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J. 1995;16:741–751[Free Full Text]
  2. American College of Cardiology/American Heart Association, Task Force Report. Guidelines for the evaluation and management of heart failure. Circulation. 1995;92:2764–2784[Free Full Text]
  3. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504–2507[Free Full Text]
  4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–254[Abstract]
  5. Harris P. Role of arterial pressure in the oedema of heart disease. Lancet. 1988;i:1036–1038
  6. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650–655
  7. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med. 1984;;311:819–823[Abstract]
  8. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol. 1991;69:523–531
  9. Mortara A, La Rovere MT, Signorini MG, et al. Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and afte transplantation. Br Heart J. 1994;71:422–430[Abstract/Free Full Text]
  10. Ceconi C, Curello S, Ferrari R. Catecholamines: the cardiovascular and neuroendocrine system. Eur Heart J. 1998;19:F2–F6
  11. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall cardiorenal sympathetic nervous activity. Circulation. 1986;73:615–621[Abstract/Free Full Text]
  12. Anversa P, Olivetti G, Capobasso JM. Cellular basis of ventricular remodelling after myocardial infaretion. Am J Cardiol. 1991;68:7–16[Web of Science][Medline]
  13. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Circulation. 1990;181:1161–1172
  14. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamines sensitivity and ß-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205–211[Abstract]
  15. Braunwald F. Heart Disease. A Texbook of Cardiovascular Medicine. Philadelphia: Saunders; 2001.
  16. Ferrari R, Ceconi C, Curello S, et al. Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? Cardiovase Drugs Ther. 1996;10:639–647[CrossRef]
  17. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–254
  18. Riegger AJ, Lieblau G, Holzschuh M, Witkowski D, Steilner H, Kochsiek K. Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting enzyme blockade. Am J Cardiol. 1984;53:614–618[CrossRef][Web of Science][Medline]
  19. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation. 1993;87:2016–2022[Abstract/Free Full Text]
  20. Francis GS, Rector TS, Cohn JN. Sequential neurohumoral measurements in patients with congestive heart failure. Am Heart J. 1988;116:1464–1468[CrossRef][Web of Science][Medline]
  21. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–1729[Abstract/Free Full Text]
  22. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol. 1990;66:40D–44D[CrossRef][Medline]
  23. Francis GS, Cohn IN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:V140–V148
  24. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnizky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992;85:164–171[Abstract/Free Full Text]
  25. Mortara A, Speccha G, La Rovere MT, et al. Patency of infarctrelated artery. Effect of restoration on anterograde flow on vagal reflexes. ATRAMI (Automatic Tone and Reflexes After Myocardial Infarction) Investigators. Circulation. 1996;93:1114–1122[Abstract/Free Full Text]
  26. Cohn JN, Levine TB, Olivari MT, et al. Plasma noradrenaline as a guide to prognosis in patients with congestive heart failure. N Engl J Med. 1984;311:819–823
  27. Cohn JN, Johnson GR, Shabetai R. for the V HeFT VA Cooperative studies group. Circulation. 1993;87:5–16
  28. Lechat P, Paker M, Chalon S, et al. Clinical effects of beta adrenergic blockade in chronic heart failure. Circulation. 1998;98:1184–1191[Abstract/Free Full Text]
  29. Packer M, Bristow MR, Cohn JNfor the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  30. Packer M. Effects of beta adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol. 1997;80:462–544
  31. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375–380[CrossRef][Web of Science][Medline]
  32. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-wilson PA, Harris P. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305[Abstract/Free Full Text]
  33. Bayliss J, Norell M, Canepa-anson R, Sutton G, Poole-wilson PA. Clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22[Abstract/Free Full Text]
  34. Watkins L Jr, Burton JA, Haber E, Cant JR, Smith F, Barger A. The renin-angiotensin-aldosterone system in congestive heart failure in conscious dogs. J Clin Invest. 1976;57:1606–1617
  35. Weber KT. Extracellular matrix remodelling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065–4082[Free Full Text]
  36. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730–1736[Abstract/Free Full Text]
  37. Staessen J, Lijnen P, Fagard R, Verschucren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457–465[Abstract/Free Full Text]
  38. Ferrari R, Ceconi C. Neuroendocrine activation in left ventricular dysfunction. Eur Heart J. 1998;19:1423–1424
  39. Perry WF, Fyles TW. Antidiuretic activity of the serum of normal and diseased subjects. Clin Endocrin Metab. 1953;13:64–72
  40. Echemann D, Cooper HA, Rinow S, et al. Determinants of angiotensin converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the Epical Study. Am Heart J. 2000;139:624–636[Web of Science][Medline]
  41. The Network Investigators. Clinical Outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 1998;19:481–489[Abstract/Free Full Text]
  42. Ferrari R, Ceconi C, Curello S, Pepi P, Mazzoletti A, Visioli O. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Cardiovasc Drugs Ther. 1996;10:623–629
  43. Ferrari R. Effect of ACE inhibition on myocardial ischemia. Eur Heart J. 1998;19:J30–J35
  44. Pitt B, Zannad F, Remme W. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  45. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan vs captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  46. Pitt B. Effect of losartan compared with captopril on mortality of patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Sirvival Study ELITE 11. Lancet. 2000;355:1582–1587[CrossRef][Web of Science][Medline]
  47. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675[Abstract/Free Full Text]
  48. De Bold AJ. Heart atria granularity. Effects of changes in water electrolyte balance. Proc Soc Exp Biol Med. 1979. p. 508–511
  49. Ferrari R, Agnoletti G. Atrial natriuretic peptide: its mechanism of release from the atrium. Int J Cardiol. 1989;24:137–149[CrossRef][Web of Science][Medline]
  50. Cody JR, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 1986;78:1362–1374
  51. Raine AEG, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986;315:553
  52. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–1942[Abstract/Free Full Text]
  53. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endotelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76:803–808[CrossRef][Web of Science][Medline]
  54. Wallen T, Landhal S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 1997;77:264–267[Abstract/Free Full Text]
  55. McDonagh TA, Robb SD, Urdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13[CrossRef][Web of Science][Medline]
  56. Anand IS, Kalra GS, Ferrari R, Wahi PL, Harris P, Poole-Wilson PA. Hemodynamic, hormonal, and renal effects of atrial natriuretic peptide in untreated congestive heart failure. Am Heart J. 1989;118:500–505[CrossRef][Web of Science][Medline]
  57. Cavern PG, Margulies KB, Winaver J, Seymour AA, Delaney NG, Burnett JC Jr. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 1990;82:196–201[Abstract/Free Full Text]
  58. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641[Abstract]
  59. Cleland JG, Dargie HJ, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J. 1987;58:572–582[Abstract/Free Full Text]
  60. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641
  61. Saki S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Injibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355[CrossRef][Medline]
  62. Anker SD, Chua TP, Ponikowaki P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance in cardiac cachexia. Circulation. 1997;96:526–534[Abstract/Free Full Text]
  63. Fazio S, Sabatini L, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809–814[Abstract/Free Full Text]
  64. Ferrari R, Panzali AF, Poole-Wilson PA, Anand IS. Plasma immunoreactive CGRP-like activity in treated and untreated congestive heart failure. Lancet. 1991;338:1084–1089[Web of Science][Medline]
  65. Anand IS, Gurden J, Wander GS, et al. Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. J Am Coll Cardiol. 1991;17:208–217[Abstract]
  66. Anand IS. Pathogenesis of salt and water retention in the congestive heart failure syndrome. Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJ. Heart Failure. New York: Churchill Livingstone; 1997. p. 155–172
  67. Ferrari R, Ceconi C, de Giuli F, Panzali A, Harris P. Temporal relations of the endocrine response to hypotension with sodium nitroprusside. Cardioscience. 1992;3:51–60[Web of Science][Medline]
  68. Ceconi C, Rodella A, de Giuli F, Panzali A, Harris P. Temporal relations of the endocrine response to exercise. Cardioscience. 1991;2:131–139[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
V. J Colucci and B. D Berry
Heart Failure Worsening and Exacerbation After Venlafaxine and Duloxetine Therapy
Ann. Pharmacother., June 1, 2008; 42(6): 882 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Ferrari
Physical training in chronic heart failure: much more than training
Eur. Heart J., December 1, 2002; 23(23): 1803 - 1804.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?